10.14.2015 - Neuro Advance Boston

"What's Hot in NeuroD" Panel to Feature LTI's CSO, Peter Lansbury

01.10.2017 – FierceBiotech

Allergan keeps the dealmaking pedal firmly pressed with two new deals for Parkinson's, GI drugs


01.10.2017 – PharmaTimes

Allergan broadens pipeline with Parkinson’s disease deal


01.09.2017 - Boston Business Journal

Allergan wants to buy a Cambridge biotech founded by ex-Genzyme CEO


01.09.2017 - Endpoints

Allergan bags two new deals, takes option to buy Lysosomal Therapeutics and pays $50M for microbiome pact


01.09.2017 – Genetic Engineering & Biotechnology News

Allergan Broadening GI Pipeline, Expanding into Parkinson's


01.09.2017 – Forbes

Potential Breakthrough Option For Parkinson's: LTI Partners With Allergan


01.09.2017 – TheStreet

Allergan Continues Down 'Stepping Stone' Path With Two Deals


01.09.2017 – BioCentury

Allergan in deals with Lysosomal Therapeutics, Assembly


01.09.2017 – Xconomy

Allergan, Eying More Neurodegenerative Drugs, Gets Right to Buy LTI


07.14.2015 - Genetic Engineering & Biotechnology News

​Parkinsons' Disease: The Devil Is in the Protein


02.20.2015 - Boston Business Journal

Lysosomal Therapeutics to use $20M to develop, test Parkinson's drug


02.03.2015 - Xconomy

As Promised, LTI Pulls In Big Series A to Advance Parkinson's Drug


02.03.2015 - MedCity News

Lysosomal Therapeutics raises $20M Series A from Sanofi, Lilly and Roche for Parkinson's drug


02.03.2015 - Venturewire

Lysosomal Therapeutics Receives $20M Series A for Parkinson's Disease Therapy


02.03.2015 - FierceBiotech

Sanofi, Roche and Lilly help bankroll a $20M round for Parkinson's player LTI


02.03.2015 - BioCentury

Insiders back Lysosomal in $20M A round


02.03.2015 - Chemical & Engineering News

Chemistry-Based Biotech Star-Ups Secure Funding


01.15.2015 - Xconomy

Attacking Parkinson's Via Gaucher Link, LTI Ready for Its Series A


06.12.2014 - Start-Up

Unpacking Lysosomal Storage: New Insights Drive Parkinson's Drug Development


05.26.2014 - BioCentury

Emerging Company Profile - Lysosomal: Activating GCase


05.14.2014 - WBZ News Radio

Cambridge Company Raises $5M in Quest to Discover Drug to Treat Parkinson's


05.13.2014 - FierceBiotech

Startup brings together some of Boston's top biotech brains and bucks


05.13.2014 - BioWorld Today

LTI taps lysosomal experts, model for Parkinson's work


05.12.2014 - Xconomy

LTI Corrals $5M to Exploit Link Between Gaucher, Parkinson's


05.12.2014 - MedCity News

Ex-Genzyme CEO's new company looks to rare diseases for insight into treating Parkinson's


05.12.2014 - BioCentury Extra

Lysosomal raises $4.8 million in seed financing


05.12.2014 - Mass High Tech's BioFlash

Former Genzyme CEO Henri Termeer co-founds biotech aimed at Parkinson's


05.12.2014 - BetaBoston / Boston Globe

Lysosomal, founded by Genzyme vets, raises $4.8 million

Events

Press Releases

LTI in the News

 Press Releases, Events and News




Delivering cures for neurodegenerative diseases. 

​​Lysosomal Therapeutics Inc.​​

01.10.2017 – FierceBiotech

Allergan keeps the dealmaking pedal firmly pressed with two new deals for Parkinson's, GI drugs


01.10.2017 – PharmaTimes

Allergan broadens pipeline with Parkinson’s disease deal


01.09.2017 - Boston Business Journal

Allergan wants to buy a Cambridge biotech founded by ex-Genzyme CEO


01.09.2017 - Endpoints

Allergan bags two new deals, takes option to buy Lysosomal Therapeutics and pays $50M for microbiome pact


01.09.2017 – Genetic Engineering & Biotechnology News

Allergan Broadening GI Pipeline, Expanding into Parkinson's


01.09.2017 – Forbes

Potential Breakthrough Option For Parkinson's: LTI Partners With Allergan


01.09.2017 – TheStreet

Allergan Continues Down 'Stepping Stone' Path With Two Deals


01.09.2017 – BioCentury

Allergan in deals with Lysosomal Therapeutics, Assembly


01.09.2017 – Xconomy

Allergan, Eying More Neurodegenerative Drugs, Gets Right to Buy LTI


07.14.2015 - Genetic Engineering & Biotechnology News

​Parkinsons' Disease: The Devil Is in the Protein


02.20.2015 - Boston Business Journal

Lysosomal Therapeutics to use $20M to develop, test Parkinson's drug


02.03.2015 - Xconomy

As Promised, LTI Pulls In Big Series A to Advance Parkinson's Drug


02.03.2015 - MedCity News

Lysosomal Therapeutics raises $20M Series A from Sanofi, Lilly and Roche for Parkinson's drug


02.03.2015 - Venturewire

Lysosomal Therapeutics Receives $20M Series A for Parkinson's Disease Therapy


02.03.2015 - FierceBiotech

Sanofi, Roche and Lilly help bankroll a $20M round for Parkinson's player LTI


02.03.2015 - BioCentury

Insiders back Lysosomal in $20M A round


02.03.2015 - Chemical & Engineering News

Chemistry-Based Biotech Star-Ups Secure Funding


01.15.2015 - Xconomy

Attacking Parkinson's Via Gaucher Link, LTI Ready for Its Series A


06.12.2014 - Start-Up

Unpacking Lysosomal Storage: New Insights Drive Parkinson's Drug Development


05.26.2014 - BioCentury

Emerging Company Profile - Lysosomal: Activating GCase


05.14.2014 - WBZ News Radio

Cambridge Company Raises $5M in Quest to Discover Drug to Treat Parkinson's


05.13.2014 - FierceBiotech

Startup brings together some of Boston's top biotech brains and bucks


05.13.2014 - BioWorld Today

LTI taps lysosomal experts, model for Parkinson's work


05.12.2014 - Xconomy

LTI Corrals $5M to Exploit Link Between Gaucher, Parkinson's


05.12.2014 - MedCity News

Ex-Genzyme CEO's new company looks to rare diseases for insight into treating Parkinson's


05.12.2014 - BioCentury Extra

Lysosomal raises $4.8 million in seed financing


05.12.2014 - Mass High Tech's BioFlash

Former Genzyme CEO Henri Termeer co-founds biotech aimed at Parkinson's


05.12.2014 - BetaBoston / Boston Globe

Lysosomal, founded by Genzyme vets, raises $4.8 million